Fusion IP
VC Fund
Sheffield, United Kingdom
Fusion IP is a VC fund in Sheffield focused on Biotechnology and Health Care. Fusion IP owns the rights to 100% of university-owned research generated at two of the UK's leading universities - The University of Sheffield and Cardiff University. These exclusive partnerships enable us to develop some of the world's most advanced and exciting science, in fields as varied as clean energy, electronics, engineering andmedicine; turning world class research into valuable businesses through the creation of portfolio of companies.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Fusion IP invests in
Stages Fusion IP invests in
Countries Fusion IP invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Aidong Xu
|
|||
Bob Rabone
|
|||
Craig Richardson
|
|||
Keith Wreggett
|
|||
Natalie Wilkinson
|
|||
| See all 8 contacts → | |||
Investment Focus
Industry
- Biotechnology 3 (75%)
- Health Care 2 (50%)
- Energy 1 (25%)
- Hardware 1 (25%)
- Biopharma 1 (25%)
Stage
- Funding Round 3 (75%)
- Seed 1 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Aidong Xu
Business Manager
|
Business Manager | Total investments: 0 | Find email | |
|
Bob Rabone
Non-executive Director
|
Non-executive Director | Total investments: 0 | Find email | |
|
Craig Richardson
Commercial ManagerLife Sciences
|
Commercial ManagerLife Sciences | Total investments: 0 | Find email | |
|
Keith Wreggett
Commercial Manager
|
Commercial Manager | Total investments: 0 | Find email | |
|
Natalie Wilkinson
Office Manager
|
Office Manager | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Exonate is a privately held, early stage, biotech company spun out of the University of Nottingham that is focused on alternative splicing of Vascular Endothelial Growth Factor (VEGF) in ophthalmology. Exonate’s lead programme is focused on Diabetic Macular Oedema (DMO). A consequence of diabetic retinopathy, DMO, is swelling in an area of theretina called the macula and wet Age-Related Macular Degeneration (wAMD), which is the leading cause of vision loss in people aged 60 and older. The Company is founded on scientific excellence with strong links to Professor David Bates and his lab at Nottingham University specializing in the biology and biochemical pathways of VEGF splice variants.Exonate have developed small molecules that inhibit production of pro-angiogenic VEGF through selective inhibition of serine/threonine-protein kinase 1 (SRPK1)-mediated VEGF splicing. These inhibitors have already demonstrated superior efficacy as topical agents in preclinical models of wet AMD. Through a Wellcome Trust funded project, Exonate has completed an optimization programme and has nominated a pre-clinical candidate drug with optimal characteristics.During the second quarter of 2020 regulatory toxicology and safety pharmacology studies have taken place. This is to support the successful application to the regulatory authorities for clinical evaluation. Exonate is led by an experienced, international management team that has previously worked together with cross-disciplinary experience in medicine and drug development, as well as successful fundraising for early stage companies.About Diabetic Macular Oedema (DMO)*: DMO is the build-up of fluid (Oedema) in a region of the retina called the macula. The macula is important for the sharp, straight-ahead vision that is used for reading, recognizing faces, and driving. DMO is the most common cause of vision loss among people with diabetic retinopathy. About half of all people with diabetic retinopathy will develop DMO and although it is more likely to occur as diabetic retinopathy worsens, DMO can happen at any stage of the disease.About wet Age-Related Macular Degeneration (wet AMD): Today, wet AMD is a leading cause of vision loss in people aged 60 years or older and affects more than 30 million patients worldwide, over 200,000 of those in the UK alone. If untreated patients are likely to lose sight in the affected eye within 24 months of disease onset.The main currently available treatment options for DMO and wet AMD are: • anti-VEGF antibody drugs – to prevent the growth of new blood vessels in the eye. Unlike small molecule drugs or eye drops these treatments must be injected into the eye once every 1 or 2 months. Resistance can develop to these drugs causing the disease to progress anew. • Laser surgery – to destroy abnormal blood vessels in the eye. This type of surgery is only suitable if blood vessel damage is not too extensive and if the abnormal blood vessels aren't close to the fovea, as performing surgery close to this part of the eye can cause permanent vision loss. • With DMO, Corticosteroids either injected or implanted into the eye, may be used alone or in combination with other drugs or laser surgery to treat DMO.*source: https://nei.nih.gov/health/diabetic/retinopathy | $524K / Seed / Nov 03, 2013 | ||
| Magnomatics is a high technology spin-out company from the largest electrical machines research group in the UK.Magnomatics was established in 2006 as a spin-out from the University of Sheffield to commercialise ground-breaking research on magnetic transmission systems, high-torque electrical machines and electromechanical actuators and dampersbeing undertaken by Dr Kais Atallah and Professor David Howe in the Electrical Machines and Drives research group at the University. | $3.3M / Nov 22, 2012 | ||
| Phase Focus has developed a proprietary process that can generate high definition images of an object without the need for high quality lenses. The technique uses a novel iterative phase retrieval algorithm to generate both amplitude and phase images of an object and has applications in optical, X-ray and electron microscopy, amongst others. | $5M / Jun 29, 2012 | ||
| CellTran Limited engages in the research and development of products for the regeneration of tissue and the healing of wounds. The company offers Myskin that is used for the treatment of difficult to heal wounds; Lyphoderm, a freeze-dried lysate from cultured human keratinocytes that is formulated into a hydrophilic gel; and Ulcodress, anintegrated wound care dressing that provides control of moisture, infection, and proteases within the wound area. It provides skin banking services, as well as contract manufacture services in the fields of materials fabrication and cell culture. The company was founded in 2000 and is based in Sheffield, the United Kingdom. As of October 28, 2008, CellTran Limited operates as a subsidiary of York Pharma plc. | $4.8M / Aug 09, 2005 |
Co-Investors
Finance Yorkshire
1 deal together
IP Group
1 deal together
Ombu Group
1 deal together
Partnerships UK
1 deal together
Spirit Capital Partners
1 deal together
University of Nottingham
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Fusion IP invest in?
Fusion IP invests primarily in Biotechnology, Health Care and Energy startups, most often at Funding Round and Seed stage. Most of the 4 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Fusion IP?
Public channels for Fusion IP include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Fusion IP?
The team at Fusion IP includes Aidong Xu (Business Manager), Bob Rabone (Non-executive Director) and Craig Richardson (Commercial ManagerLife Sciences), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
